A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

Nature Medicine

Volumn 22, Issue 7, 2016, Pages 744-753

  Dauch, Daniel ^a   Rudalska, Ramona ^a   Cossa, Giacomo ^b   Nault, Jean Charles ^c   Kang, Tae Won ^a,d   Wuestefeld, Torsten ^a   Hohmeyer, Anja ^a   Imbeaud, Sandrine ^c   Yevsa, Tetyana ^a   Hoenicke, Lisa ^a   Pantsar, Tatu ^e   Bozko, Przemyslaw ^a   Malek, Nisar P ^a   Longerich, Thomas ^f   Laufer, Stefan ^a   Poso, Antti ^a,e   Zucman Rossi, Jessica ^c   Eilers, Martin ^b,g   Zender, Lars ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c INSERM   (France)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2D; DANUSERTIB; MYC PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; AZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD532 COMPOUND; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; N-RAS PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN P21; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME MECHANISM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINT; DRUG SCREENING; GENE DELETION; GENETICS; KNOCKOUT MOUSE; LIVER CELL; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION;

ANIMALS; AURORA KINASE A; AZEPINES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MONOMERIC GTP-BINDING PROTEINS; MUTATION; ONCOGENE PROTEIN P21(RAS); PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969836565     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4107     Document Type: Article

References (60)

1. Eilers, M. and Eisenman, R.N. Mycs broad reach. Genes Dev. 22, 2755-2766 (2008).
2. Meyer, N. and Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990 (2008).
3. Soucek, L. et al. Modeling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008).
4. Shachaf, C.M. et al. MYC inactivation uncovers pluripotent differentiation and tumor dormancy in hepatocellular cancer. Nature 431, 1112-1117 (2004).
5. Felsher, D.W. and Bishop, J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
6. Podsypanina, K., Politi, K., Beverly, L.J. and Varmus, H.E. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc. Natl. Acad. Sci. USA 105, 5242-5247 (2008).
7. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia. Nature 478, 524-528 (2011).
8. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
9. Otto, T. et al. Stabilization of NMYC is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).
10. Brockmann, M. et al. Small-molecule inhibitors of Aurora A induce proteasomal degradation of N-MYC in childhood neuroblastoma. Cancer Cell 24, 75-89 (2013).
11. Gustafson, W.C. et al. Drugging MYCN through an allosteric transition in aurora kinase A. Cancer Cell 26, 414-427 (2014).
12. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495 (2011).
13. Mosquera, J.M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal-treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1-10 (2013).
14. Bruix, J., Gores, G.J. and Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 63, 844-855 (2014).
15. Lord, R., Suddle, A. and Ross, P.J. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int. J. Clin. Pract. 65, 182-188 (2011).
16. Welsch, C., Jesudian, A., Zeuzem, S. and Jacobson, I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 (suppl. 1), i36-i46 (2012).
17. Calle, E.E. and Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
18. White, D.L., Kanwal, F. and El-Serag, H.B. Association between non-alcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10, 1342-1359.e2 (2012).
19. Liu, J. et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur. J. Cancer 48, 2328-2338 (2012).
20. Chan, K.L., Guan, X.Y. and Ng, I.O. High-throughput tissue microarray analysis of c-Myc activation in chronic liver diseases and hepatocellular carcinoma. Hum. Pathol. 35, 1324-1331 (2004).
21. Meek, D.W. Tumor suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 9, 714-723 (2009).
22. Sherr, C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998).
23. Tannapfel, A. et al. INK4A-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 20, 7104-7109 (2001).
24. Sherr, C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673 (2006).
25. Carlson, C.M., Frandsen, J.L., Kirchhof, N., McIvor, R.S. and Largaespada, D.A. Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc. Natl. Acad. Sci. USA 102, 17059-17064 (2005).
26. Kang, T.W. et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature 479, 547-551 (2011).
27. Wuestefeld, T. et al. A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 153, 389-401 (2013).
28. Tward, A.D. et al. Genomic progression in mouse models for liver tumors. Cold Spring Harb. Symp. Quant. Biol. 70, 217-224 (2005).
29. Rudalska, R. et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138-1146 (2014).
30. Calvisi, D.F. et al. Ubiquitous activation of RAS and JAK-STAT pathways in human HCC. Gastroenterology 130, 1117-1128 (2006).
31. Schmidt, C.M., McKillop, I.H., Cahill, P.A. and Sitzmann, J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236, 54-58 (1997).
32. Ito, Y. et al. Activation of mitogen-activated protein kinases-extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27, 951-958 (1998).
33. Crane, R., Gadea, B., Littlepage, L., Wu, H. and Ruderman, J.V. Aurora A, meiosis and mitosis. Biol. Cell 96, 215-229 (2004).
34. Katayama, H., Brinkley, W.R. and Sen, S. The aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22, 451-464 (2003).
35. Katsha, A., Belkhiri, A., Goff, L. and El-Rifai, W. Aurora kinase A in gastrointestinal cancers: time to target. Mol. Cancer 14, 106 (2015).
36. Lu, L.Y. et al. Aurora A is essential for early embryonic development and tumor suppression. J. Biol. Chem. 283, 31785-31790 (2008).
37. Kimura, M.T. et al. Two functional coding single-nucleotide polymorphisms in STK15 (aurora A) coordinately increase esophageal cancer risk. Cancer Res. 65, 3548-3554 (2005).
38. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. and Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B (AKT) cellular survival pathway. EMBO J. 16, 2783-2793 (1997).
39. Klein, A., Flugel, D. and Kietzmann, T. Transcriptional regulation of serine/threonine kinase 15 (STK15) expression by hypoxia and HIF-1. Mol. Biol. Cell 19, 3667-3675 (2008).
40. Farazi, P.A. and DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006).
41. Perez Tamayo, R. Is cirrhosis of the liver experimentally produced by CCl4 an adequate model of human cirrhosis? Hepatology 3, 112-120 (1983).
42. Taub, R. Liver regeneration 4: transcriptional control of liver regeneration. FASEB J. 10, 413-427 (1996).
43. White, P., Brestelli, J.E., Kaestner, K.H. and Greenbaum, L.E. Identification of transcriptional networks during liver regeneration. J. Biol. Chem. 280, 3715-3722 (2005).
44. Yuan, H. et al. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis 33, 285-293 (2012).
45. Carpinelli, P. et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6, 3158-3168 (2007).
46. Aliagas-Martin, I. et al. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. J. Med. Chem. 52, 3300-3307 (2009).
47. Fancelli, D. et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49, 7247-7251 (2006).
48. Falchook, G. et al. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in nonhematologic malignancies: phase 1 dose-escalation study. Invest. New Drugs 32, 1181-1187 (2014).
49. Amati, B. Myc degradation: dancing with ubiquitin ligases. Proc. Natl. Acad. Sci. USA 101, 8843-8844 (2004).
50. Eilers, M., Schirm, S. and Bishop, J.M. The MYC protein activates transcription of the α-prothymosin gene. EMBO J. 10, 133-141 (1991).
51. Watson, J.D., Oster, S.K., Shago, M., Khosravi, F. and Penn, L.Z. Identifying genes regulated in a Myc-dependent manner. J. Biol. Chem. 277, 36921-36930 (2002).
52. Lu, L. et al. Aurora kinase A mediates c-Mycs oncogenic effects in hepatocellular carcinoma. Mol. Carcinog. 54, 1467-1479 (2015).
53. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
54. Burgess, D.J. et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. USA 105, 9053-9058 (2008).
55. Braumuller, H. et al. T helper 1 cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013).
56. Huesken, D. et al. Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23, 995-1001 (2005).
57. Vert, J.P., Foveau, N., Lajaunie, C. and Vandenbrouck, Y. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7, 520 (2006).
58. Zender, L. et al. Caspase-8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA 100, 7797-7802 (2003).
59. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667 (2008).
60. Diefenbacher, M.E. et al. Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer Res. 75, 1181-1186 (2015).